L152
For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. But the benefit for most women was small, Immunotherapy Shows Modest Progress Against Breast Cancer
raising questions about whether the treatment is worth its high cost and side effects.
Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine.
Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.
The new study tested one from Roche called Tecentriq plus chemo versus chemo alone in 902 women with advanced triple-negative breast cancer. About 15 percent of cases are this type, their growth is not fueled by the hormones estrogen or progesterone, or the gene that Herceptin targets, making them hard to treat.
Women in the study who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone, a modest benefit. The combo did not significantly improve survival in an early look before long-term follow-up is complete.
Previous studies found that immunotherapies work best in patients with high levels of a protein that the drugs target, and the plan for the breast cancer study called for analyzing how women fared according to that factor if Tecentriq improved survival overall.
The drug failed that test, but researchers still looked at protein-level results and saw encouraging signs. Women with high levels who received the combo treatment lived roughly 25 months on average versus about 15 months for women given chemo alone.
That’s a big difference, but it will take more time to see if there’s a reliable way to predict benefit, said Dr. Jennifer Litton of the MD Anderson Cancer Center in Houston. She had no role in running the study but enrolled some patients in it and oversees 14 others testing immunotherapies.
“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” she said.
Another breast cancer specialist with no role in the study, Dr. Michael Hassett at Dana-Farber Cancer Institute in Boston, said he felt “cautious excitement” that immunotherapy may prove helpful for certain breast cancer patients.
Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts, but serious ones were more common with the combo treatment and twice as many women on it stopped treatment for that reason.
Three of the six deaths from side effects in the combo group were blamed on the treatment itself; only one of three such deaths in the chemo group was.
Cost is another concern. Tecentriq is $12,500 a month. The chemo in this study was Celgene’s Abraxane, which costs about $3,000 per dose plus doctor fees for the IV treatments. Older chemo drugs cost less but require patients to use a steroid to prevent allergic reactions that might interfere with the immunotherapy. Abraxane was chosen because it avoids the need for a steroid, said one study leader, Dr. Sylvia Adams of NYU Langone Health.
The study was sponsored by Roche and many study leaders consult or work for the company or own stock in it.
L152的更多相关文章
- WPF的"路径标记语法"
在此之前我们先了解一下WPF的"路径标记语法" M:表示绘制起点 // M 0,0 L:表示绘制直线 (H:横线 V:竖线) // L 100,0 C:三次方贝塞尔曲线 // ...
- Beego源码分析(转)
摘要 beego 是 @astaxie 开发的重量级Go语言Web框架.它有标准的MVC模式,完善的功能模块,和优异的调试和开发模式等特点.并且beego在国内企业用户较多,社区发达和Q群,文档齐全, ...
- 详解WPF Blend工具中的复合路径功能 ( 含路径标记语法 )
写此文章的目的是为了简单分析一下 Blend工具中提供的"复合路径"功能.有人在我的博文中留言问我复合路径的问题. 稍微琢磨一下,觉得应该是对的.因此贴出来和大家分享.有不对的说 ...
- CoreCLR源码探索(二) new是什么
前一篇我们看到了CoreCLR中对Object的定义,这一篇我们将会看CoreCLR中对new的定义和处理 new对于.Net程序员们来说同样是耳熟能详的关键词,我们每天都会用到new,然而new究竟 ...
- Linux进程退出详解(do_exit)--Linux进程的管理与调度(十四)
Linux进程的退出 linux下进程退出的方式 正常退出 从main函数返回return 调用exit 调用_exit 异常退出 调用abort 由信号终止 _exit, exit和_Exit的区别 ...
- kafka-producer配置
kafka-producer版本对比 Kafka的producer的API根据版本的不同分为kafka0.8.1.X之前的 kafka.javaapi.producer.Producer.以及之后版本 ...
- 动态svg效果
import React from 'react'; import TweenOne from 'rc-tween-one'; import SvgDrawPlugin from 'rc-tween- ...
- [转载]amba_device使用分析
什么是AMBA? ---AMBA是一个片内总线规范. ARM官网的介绍:http://infocenter.arm.com/help/index.jsp?topic=/com.arm.doc.ddi0 ...
- CoreCLR源码2
CoreCLR源码 前一篇我们看到了CoreCLR中对Object的定义,这一篇我们将会看CoreCLR中对new的定义和处理new对于.Net程序员们来说同样是耳熟能详的关键词,我们每天都会用到ne ...
随机推荐
- IPMI的几个问题
IPMI针对大量监控.控制和自动回复服务器的作业,提供了智能型的管理方式.此标准适用于不同的服务器拓朴学,以及Windows.Linux. Solaris.Mac或是混合型的操作系统.此外,由于IPM ...
- MVc分页【关于使用扩展方法实现MVc分页】
近期对MVc自定义分页作了一下小研究下面把他记下来 下述代1,2,3里面的代码可以直接拷贝,4以后的根据情况自己选定 1.在后台任写如下的扩展方法(任一类库都可以,但是用时得引用命名空间) // 添加 ...
- mybatis家族
mybatis 优秀的持久层框架,它支持定制化SQL.存储过程以及高级映射. 备注:通过mapper实现数据库与实体类相互映射 MyBatis 避免了几乎所有的JDBC 代码和手动设置参数以及获取结果 ...
- linux目录结构及文件权限
安装banner用到的指令: 第一步: sudo apt-get update 第二步: sudo apt-get install sysvbanner 成功了 创建新用户指令: sudo addus ...
- [BZOJ2809]dispatching
Description 在一个忍者的帮派里,一些忍者们被选中派遣给顾客,然后依据自己的工作获取报偿.在这个帮派里,有一名忍者被称之为 Master.除了 Master以外,每名忍者都有且仅有一个上级. ...
- [CF1042F]Leaf Sets
题意:给定一棵$n$个点的树,将叶子节点分为数个集合使集合里点对最长距离不超过$k$,求最少集合数.($n\le1000000$) 首先我们可以想到,这道题并不是让你构造最优方案,因为只要把所有叶子节 ...
- MySQL 删除重复记录
==========A really easy way to do this is to add a UNIQUE index on the 3 columns. When you write the ...
- ADO.net笔记
1.DbConnectionConnection对象也称为数据库连接对象,Connection对象的功能是负责对数据源的连接.所有Connection对象的基类都是DbConnection类.Conn ...
- ColKang v1.0
/* *2015.3.31 14:00更新 *上午刚写完这篇博客,下午就读到迭代器了.C++ primer中讲迭代器那节说道了->符号的意思,即(*ptr). 及将指针解引用之后再调用成员函数 ...
- JSON的多样格式
//JSON – Properties 方便前台列表显示 [{"年月":2002.01,"北京分公司":2214688,"河北分公司":3 ...